Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Diabetes

Free Subscription 08.12.2025 1 Am J Cardiol 1 Am J Hypertens 1 Diabet Med 2 Diabetes 3 Diabetes Care 17 Diabetes Obes Metab 1 Invest Ophthalmol Vis Sci 3 J Clin Invest 4 J Diabetes Complications 1 J Hypertens 4 N Engl J Med 1 Nutr Metab (Lond) 1 Pediatr Diabetes 4 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Cardiol

1. PHAGU AAS, van Oort MJH, Oliveri F, Bingen BO, et al
   Intravascular Lithotripsy in Diabetic Patients Undergoing Percutaneous Coronary Intervention: Long-Term Outcomes from the BENELUX Registry.
   Am J Cardiol. 2025 Nov 27:S0002-9149(25)00691.
   PubMed         Abstract available
   
   

   
   Am J Hypertens

2. MOUSAVI A, Shojaei S, Hosseini K
   Response to "Treatment Targets for Blood Pressure Lowering in Patients With Diabetes Mellitus".
   Am J Hypertens. 2025 Oct 11:hpaf187. doi: 10.1093.
   PubMed        
   
   

   
   Diabet Med

3. RICKARD X, Longfield MSG, Zhou J, Ibiebele I, et al
   The impact of obesity on pregnancy outcomes in women with type 1 and type 2 diabetes across the NSW population: A retrospective cohort study.
   Diabet Med. 2025 Dec 3:e70177. doi: 10.1111/dme.70177.
   PubMed         Abstract available
   
   

   
   Diabetes

4. ZHAO LP, Papadopoulos GK, Skyler JS, Parikh HM, et al
   Profiling Associations Between IGHG-FCGR Ligand-Receptor Interactions and Disease Progression From Stage 1 and 2 to Stage 3 Type 1 Diabetes.
   Diabetes. 2025 Dec 3:db250610. doi: 10.2337/db25-0610.
   PubMed         Abstract available
   
   
5. UCHIDA M, Yamazaki H, Han S, Huang BZ, et al
   Multiorgan Fibrosis and Risk of Type 2 Diabetes: Genetic and Observational Evidence Highlighting a Causal Role of Pancreatic Fibrosis.
   Diabetes. 2025 Dec 1:db250629. doi: 10.2337/db25-0629.
   PubMed         Abstract available
   
   

   
   Diabetes Care

6. ELDOR R, Avraham N, Rosenberg O, Shpigelman M, et al
   Erratum. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titrati
   Diabetes Care. 2025 Dec 3:dc26er02a. doi: 10.2337.
   PubMed         Abstract available
   
   
7. SCHUMACHER LM, Bass SB, Ard J, Rubin DJ, et al
   The New Obesity Treatment Landscape: Challenges and Opportunities to Promote Shared Decision-Making in People With Obesity and Type 2 Diabetes.
   Diabetes Care. 2025 Dec 3:dci250094. doi: 10.2337/dci25-0094.
   PubMed         Abstract available
   
   
8. NAGAI K, Chung HF, Hayashi K, Dobson AJ, et al
   The Association Between Race/Ethnicity and Risk of Type 2 Diabetes in Women Varies by BMI: A Pooled Analysis of Individual Data From 15 Cohort Studies.
   Diabetes Care. 2025 Dec 2:dc251478. doi: 10.2337/dc25-1478.
   PubMed         Abstract available
   
   

   
   Diabetes Obes Metab

9. PURCELL AR, Zhen XM, Wong J, Glastras SJ, et al
   Glucagon-like peptide-1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta-analysis.
   Diabetes Obes Metab. 2026;28:296-305.
   PubMed         Abstract available
   
   
10. BARRAUD S, Aguayo GA, Cosson E, Amouyal C, et al
    Severity of complications is associated with impaired health-related quality of life in people with type 1 diabetes.
    Diabetes Obes Metab. 2025 Dec 2. doi: 10.1111/dom.70306.
    PubMed         Abstract available
    
    
11. MONAMI M, Ragghianti B, Zuffanelli A, Bordoni L, et al
    Further efficacy and safety data on bio-absorbable antibiotic delivery in calcium sulphate granules for diabetic foot osteomyelitis: Extension of the BIG D-FOOT Study.
    Diabetes Obes Metab. 2025 Dec 2. doi: 10.1111/dom.70332.
    PubMed        
    
    
12. KONG W, Fang B, Xing W
    Efficacy and safety of liraglutide in non-alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Dec 1. doi: 10.1111/dom.70301.
    PubMed         Abstract available
    
    
13. LE ROUX CW, Wharton S, Bozkurt B, Platz E, et al
    Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1).
    Diabetes Obes Metab. 2026;28:337-346.
    PubMed         Abstract available
    
    
14. AOYAMA K, Okada A, Kaneko H, Azegami T, et al
    Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database.
    Diabetes Obes Metab. 2026;28:701-710.
    PubMed         Abstract available
    
    
15. ALCIBAHY Y, Darwish R, Butler AE, Moin ASM, et al
    Pancreatic beta-cell turnover in health and disease.
    Diabetes Obes Metab. 2026;28:27-49.
    PubMed         Abstract available
    
    
16. LAMBERT F, Guillon E, Gatta-Cherifi B, Soula H, et al
    Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study.
    Diabetes Obes Metab. 2026;28:443-451.
    PubMed         Abstract available
    
    
17. SA B, Maristany A, Subramaniam A, Guillen R, et al
    Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence.
    Diabetes Obes Metab. 2026;28:50-59.
    PubMed         Abstract available
    
    
18. MILANOVIC S, Lew R, Xiong K, Casavant E, et al
    A double-blind study on ulotaront's impact on weight-related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II.
    Diabetes Obes Metab. 2026;28:94-102.
    PubMed         Abstract available
    
    
19. MILANOVIC S, Lew R, Xiong K, Casavant E, et al
    An open-label study on ulotaront's effects on insulin-glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I.
    Diabetes Obes Metab. 2026;28:103-111.
    PubMed         Abstract available
    
    
20. HISADA H, Ikeuchi K, Tsuji Y, Yamamichi N, et al
    Glucagon-like peptide-1 receptor agonist and respiratory complications after endoscopy: A Japanese nationwide cohort study.
    Diabetes Obes Metab. 2026;28:316-323.
    PubMed         Abstract available
    
    
21. RAHMAN MH, Selim S, Afsana F, Hoque MA, et al
    Safety and effectiveness of tirzepatide during Ramadan fasting: Real-world evidence from patients with type 2 diabetes in Bangladesh.
    Diabetes Obes Metab. 2025 Dec 4. doi: 10.1111/dom.70343.
    PubMed         Abstract available
    
    
22. ALISSOU M, Demangeat T, Folope V, Van Elslande H, et al
    Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.
    Diabetes Obes Metab. 2026;28:112-121.
    PubMed         Abstract available
    
    
23. HENNEY AE, Riley DR, Heague M, Roberts CA, et al
    Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach.
    Diabetes Obes Metab. 2026;28:137-150.
    PubMed         Abstract available
    
    
24. XU Z, Huang Q, Zhang X, Wang S, et al
    Reevaluating the causal link between liver fat and hyperglycaemia.
    Diabetes Obes Metab. 2026;28:231-241.
    PubMed         Abstract available
    
    
25. STUPALKOWSKA W, Henney A, Sheu EG, Alam U, et al
    Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all-cause mortality, in patients with steatotic liver disease.
    Diabetes Obes Metab. 2026;28:174-185.
    PubMed         Abstract available
    
    

    
    Invest Ophthalmol Vis Sci

26. KAKIHARA S, Zhuang K, Busza A, Fawzi AA, et al
    Macular Microaneurysms Are Associated With Chronic Kidney Disease and Deep Capillary Plexus Ischemia in Referable Diabetic Retinopathy.
    Invest Ophthalmol Vis Sci. 2025;66:3.
    PubMed         Abstract available
    
    

    
    J Clin Invest

27. KHAN S, Gaivin RJ, Liu Z, Li V, et al
    Fatty acid transport protein 2 inhibition enhances glucose tolerance through alpha cell-mediated GLP-1 secretion.
    J Clin Invest. 2025;135:e192011.
    PubMed         Abstract available
    
    
28. EIZIRIK DL, Zimath PL
    Diabetes research enters the biobank era: searching for the truth in a deep well.
    J Clin Invest. 2025;135:e199728.
    PubMed         Abstract available
    
    
29. BLACK PN, DiRusso CC
    FATP2 at the crossroads of fatty acid transport, lipotoxicity, and complex disease.
    J Clin Invest. 2025;135:e199873.
    PubMed         Abstract available
    
    

    
    J Diabetes Complications

30. FAN Q, Qin G, Du B, Kan M, et al
    Evidence-based validation of cardiovascular benefits from novel MRAs in type 2 diabetes: A meta-analysis of over 30,000 patients.
    J Diabetes Complications. 2025;40:109236.
    PubMed         Abstract available
    
    
31. IBRAHIM M, Ba-Essa EM, Ahmed A, Armstrong DG, et al
    Current primary care approaches to diabetic foot prevention and treatment.
    J Diabetes Complications. 2025;40:109231.
    PubMed         Abstract available
    
    
32. ZELJKOVIC A, Vekic J, Elrayess MA, Rizzo M, et al
    The role of small, dense lipoproteins in type-2 diabetes and maturity-onset diabetes of the young (MODY): What's new.
    J Diabetes Complications. 2025 Nov 25:109233.
    PubMed        
    
    
33. HORTON WB, Mosslemi M, Valenzuela MS, Miller RG, et al
    Baseline NT-proBNP and incident heart failure in type 1 diabetes: The epidemiology of diabetes complications study.
    J Diabetes Complications. 2025;40:109235.
    PubMed         Abstract available
    
    

    
    J Hypertens

34. RENNA NF, Ramirez EI, Arrupe MF, Ramirez JM, et al
    Ambulatory blood pressure monitoring strengthens the cardiovascular signal of GLP-1RA: a meta-analysis of blood pressure and weight mediation.
    J Hypertens. 2026;44:123-129.
    PubMed         Abstract available
    
    

    
    N Engl J Med

35. NAGAOKA T
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
    N Engl J Med. 2025;393:2276.
    PubMed        
    
    
36. JAGARLAPUDI SP
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
    N Engl J Med. 2025;393:2276.
    PubMed        
    
    
37. XIE X, Xuan X
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
    N Engl J Med. 2025;393:2276-2277.
    PubMed        
    
    
38. ROSENSTOCK J, Cox D, Denning M
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes. Reply.
    N Engl J Med. 2025;393:2277-2279.
    PubMed        
    
    

    
    Nutr Metab (Lond)

39. ZHANG D, Zheng M
    The combined effect of dietary inflammatory index and physical activity on patients with diabetic kidney disease: a cross-sectional study based on NHANES.
    Nutr Metab (Lond). 2025 Nov 28. doi: 10.1186/s12986-025-01045.
    PubMed         Abstract available
    
    

    
    Pediatr Diabetes

40. RABBONE I, Bonfanti R, Graziano G, Lombardo F, et al
    Comparative Effectiveness of Switching From First-Generation Basal Insulins to Either Glargine 300 U/mL or Degludec 100 U/mL in Children and Adolescents With Type 1 Diabetes: Results From the ISPED CARD Clinical Registry.
    Pediatr Diabetes. 2025;2025:5514402.
    PubMed         Abstract available
    
    

    
    PLoS One

41. ALHAKEEM AS, Hasturk A, Lawaetz TWH, Andersen TH, et al
    Is low birth weight associated with lower adiponectin levels? - A systematic review and meta-analysis.
    PLoS One. 2025;20:e0335598.
    PubMed         Abstract available
    
    
42. BEVERLY EA, Miller S, Schmidtgesling L, Whistler K, et al
    How coping styles moderate the relationship between diabetes distress and self-care in adults with diabetes in Appalachian Ohio: A cross-sectional survey study.
    PLoS One. 2025;20:e0337481.
    PubMed         Abstract available
    
    
43. WU YH, Li CI, Liu CS, Lin CH, et al
    Visit-to-visit glycemic variability is associated with lung function variables and lung function impairment in individuals with type 2 diabetes.
    PLoS One. 2025;20:e0337885.
    PubMed         Abstract available
    
    
44. JAHAN N, Siddiquee NH, Riva RAK, Chowdhury NU, et al
    Mechanistic insight into the antidiabetic effects of Ficus hispida fruits: Inhibition of intestinal glucose absorption and pancreatic beta-cell apoptosis.
    PLoS One. 2025;20:e0337465.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.